ACUTE PULMONARY EMBOLISM TREATED WITH TISSUE PLASMINOGEN ACTIVATOR

[1]  H. Lijnen,et al.  Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. , 1986, Circulation.

[2]  I. Palacios,et al.  Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. , 1986, Circulation.

[3]  E. Braunwald,et al.  Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. , 1986, Circulation.

[4]  E. Topol,et al.  Coronary thrombolysis with recombinant tissue-type plasminogen activator. A hematologic and pharmacologic study. , 1985, Annals of internal medicine.

[5]  R. W. Brower,et al.  DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTION , 1985, The Lancet.

[6]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[7]  J. Vermylen,et al.  Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism. , 1985, Annals of internal medicine.

[8]  R. W. Brower,et al.  RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.

[9]  Frans Van de Werf,et al.  Coronary thrombolysis with tissue-type plasminogen activator , 1985 .

[10]  T. Drake.  Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction , 1985 .

[11]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[12]  B E Sobel,et al.  Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. , 1984, Circulation.

[13]  B. Sobel,et al.  Thrombolysis, clot selectivity, and kinetics. , 1984, Circulation.

[14]  F. Van de Werf,et al.  Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. , 1984, The New England journal of medicine.

[15]  M. Jenkins,et al.  Effects of hand and machine succussion on in vitro activity of potencies of Pulsatilla , 1983 .

[16]  M. Ter-pogossian,et al.  Clot-selective coronary thrombolysis with tissue-type plasminogen activator. , 1983, Science.

[17]  A. Sasahara,et al.  Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. , 1980, The New England journal of medicine.

[18]  P. Gaffney,et al.  The sulphite precipitation method for fibrinogen measurement; its use on small samples in the presence of fibrinogen degradation products. , 1976, Clinica chimica acta; international journal of clinical chemistry.

[19]  Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study. , 1974, JAMA.

[20]  E. Freis.  Hypertension. A challenge in preventive cardiology. , 1973, Circulation.

[21]  P. Lalezari,et al.  A Rapid, Simple, Sensitive Method for Measuring Fibrinolytic Split Products in Human Serum∗ , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[22]  C. Merskey,et al.  Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. , 1966, Blood.

[23]  I. C. Michaelson,et al.  A national cooperative study in the prevention of retinal detachment--a preliminary report. , 1966, Bibliotheca ophthalmologica : supplementa ad ophthalmologica.